Model for End-Stage Liver Disease Sodium as a Predictor of Surgical Risk in Cirrhotic Patients With Ascites
- PMID: 32018142
- DOI: 10.1016/j.jss.2019.12.037
Model for End-Stage Liver Disease Sodium as a Predictor of Surgical Risk in Cirrhotic Patients With Ascites
Abstract
Background: The Model for End-Stage Liver Disease Sodium (MELD-Na) incorporates hyponatremia into the MELD score and has been shown to correlate with surgical outcomes. The pathophysiology of hyponatremia parallels that of ascites, which purports greater surgical risk. This study investigates whether MELD-Na accurately predicts morbidity and mortality in patients with ascites undergoing general surgery procedures.
Materials and methods: We used the National Surgical Quality Improvement Program database (2005-2014) to examine the adjusted risk of morbidity and mortality of cirrhotic patients with and without ascites undergoing inguinal or ventral hernia repair, cholecystectomy, and lysis of adhesions for bowel obstruction. Patients were stratified by the MELD-Na score and ascites. Outcomes were compared between patients with and without ascites for each stratum using low MELD-Na and no ascites group as a reference.
Results: A total of 30,391 patients were analyzed. Within each MELD-Na stratum, patients with ascites had an increased risk of complications compared with the reference group (low MELD-Na and no ascites): low MELD-Na with ascites odds ratio (OR) 4.33 (95% confidence interval [CI] 1.96-9.59), moderate MELD-Na no ascites OR 1.70 (95% CI 1.52-1.9), moderate MELD-Na with ascites OR 3.69 (95% CI 2.49-5.46), high MELD-Na no ascites OR 3.51 (95% CI 3.07-4.01), and high MELD-Na ascites OR 7.18 (95% CI 5.33-9.67). Similarly, mortality risk was increased in patients with ascites compared with the reference: moderate MELD-Na no ascites OR 3.55 (95% CI 2.22-5.67), moderate MELD-Na ascites OR 13.80 (95% CI 5.65-33.71), high MELD-Na no ascites OR 8.34 (95% CI 5.15-13.51), and high MELD-Na ascites OR 43.97 (95% CI 23.76-81.39).
Conclusions: MELD-Na underestimates morbidity and mortality risk for general surgery patients with ascites.
Keywords: Ascites; Cirrhosis; MELD-Na; Surgical risk.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Model for End-Stage Liver Disease Underestimates Morbidity and Mortality in Patients with Ascites Undergoing Colectomy.World J Surg. 2018 Oct;42(10):3390-3397. doi: 10.1007/s00268-018-4591-0. World J Surg. 2018. PMID: 29541825
-
Region 11 MELD Na exception prospective study.Ann Hepatol. 2012 Jan-Feb;11(1):62-7. Ann Hepatol. 2012. PMID: 22166562
-
The Refit model for end-stage liver disease-Na is not a better predictor of mortality than the Refit model for end-stage liver disease in patients with cirrhosis and ascites.Clin Mol Hepatol. 2014 Mar;20(1):47-55. doi: 10.3350/cmh.2014.20.1.47. Epub 2014 Mar 26. Clin Mol Hepatol. 2014. PMID: 24757658 Free PMC article.
-
Model for End-Stage Liver Disease-Sodium Score: The Evolution in the Prioritization of Liver Transplantation.Clin Liver Dis. 2017 May;21(2):275-287. doi: 10.1016/j.cld.2016.12.014. Clin Liver Dis. 2017. PMID: 28364813 Review.
-
Colorectal surgery in cirrhotic patients.ScientificWorldJournal. 2014 Jan 15;2014:239293. doi: 10.1155/2014/239293. eCollection 2014. ScientificWorldJournal. 2014. PMID: 24550693 Free PMC article. Review.
Cited by
-
The incidence and outcome of postoperative hepatic encephalopathy in patients with cirrhosis.United European Gastroenterol J. 2021 Jul;9(6):672-680. doi: 10.1002/ueg2.12104. Epub 2021 Jun 8. United European Gastroenterol J. 2021. PMID: 34102040 Free PMC article.
-
Prognostic Nomograms for Hospital Survival and Transplant-Free Survival of Patients with Hepatorenal Syndrome: A Retrospective Cohort Study.Diagnostics (Basel). 2022 Jun 8;12(6):1417. doi: 10.3390/diagnostics12061417. Diagnostics (Basel). 2022. PMID: 35741226 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical